ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 in the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
Sponsor: Intra-Cellular Therapies, Inc.
Terminated
Pre-specified Interim Analysis Indicated Futility
Other terminated trials from Intra-Cellular Therapies, Inc.
More terminations from Intra-Cellular Therapies, Inc.
This PHASE3 trial investigates Agitation in Dementia, Including Alzheimer's Disease and is currently terminated or withdrawn. Intra-Cellular Therapies, Inc. leads this study, which shows 13 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Sep 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 8 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Terminated PHASE3
-
Jan 2019 — Jan 2021 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Sep 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
Apr 2017 — Sep 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Intra-Cellular Therapies, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .